NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed
against the anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1;
ZIP6) protein that is conjugated, via a protease-cleavable linker, to the cytotoxic
agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon
administration and internalization by LIV-1-positive tumor cells, ladiratuzumab vedotin
undergoes enzymatic cleavage to release MMAE into the cytosol. In turn, MMAE binds
to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle
arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a member of the zinc
transporter family, is expressed in several types of solid tumors and plays a key
role in tumor cell progression and metastasis. The linkage system in ladiratuzumab
vedotin is highly stable in plasma, resulting in cytotoxic specificity against LIV-1-positive
cells.;
UNII : VM4G5D1A60;
CAS number : 1629760-29-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1629760-29-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
See also inter- (CISMeF)